Genovac enhances its antibody discovery services with the ENPICOM IGX Platform

03 May 2022 | Tuesday | News

Genovac will use ENPICOM’s world-leading cloud platform to accelerate and improve antibody discovery and early de-risking of development for clients
IGX Platform to de-risk antibody development.

IGX Platform to de-risk antibody development.

Genovac, a leading contract research and manufacturing organization (CRO/CMO) that discovers, develops, and manufactures antibodies for therapeutic, diagnostic and research market segments, and ENPICOM, an innovative bioinformatics software engineering company, announced that Genovac will use ENPICOM’s IGX Platform for their antibody discovery workflows. Genovac will rely on the IGX Platform’s advanced data management and computational analysis functionalities as part of its commitment to enabling client success and easier discovery of diverse, quality antibodies in the shortest amount of time.

"We are proud to support Genovac, one of the world’s leading CROs in antibody discovery, as they continuously seek for innovative ways to better serve their clients in pursuit of therapeutic and diagnostic products." said Jos Lunenberg, Chief Executive Officer at ENPICOM. "ENPICOM’s solutions help organizations like Genovac decode the antibody repertoire and simplify the path to scientific discovery. We are proud to support their quest to deliver high value antibodies against even the most difficult targets."

"The IGX Platform’s capabilities are truly impressive and the ENPICOM vision aligns well with our goals, so it's a natural match. We excel in delivering diverse antibody candidates for challenging targets. We’ve committed to continuous evaluation, acquisition, and development of the most advanced technologies that will dramatically increase the speed, robustness, and precision at which we discover new antibodies," said Brian Walters, Chief Executive Officer at Genovac. "By leveraging ENPICOM’s powerful data integration and analysis features, we will be able to increase our ability to unlock access to needle-in-a-haystack targets and continue to deliver the world's most advanced antibody discovery solutions to our clients."

Innovating antibody discovery at Genovac

For over 20 years, Genovac has served the biopharmaceutical industry by providing antibodies for development into clinical and commercial drugs. They have completed projects for hundreds of biopharma, biotech and research companies and institutions, specializing in the use of genetic immunization, diverse host species, and automated single B cell screening platforms for advanced discovery against challenging targets such as GPCRs and ion channels. By leveraging the IGX Platform, Genovac can now find better antibodies faster, and by leveraging its newest functionalities, screen for developable candidates in early stages of discovery.

The IGX Platform provides a complete package for the needs of innovative CROs like Genovac. The intuitive interface allows researchers to explore their data with minimal training, virtual tours smooth the onboarding process and data sharing options support collaboration. The true power of the technology lies in the antibody discovery capabilities that empower scientists to easily perform incredibly complex and computationally heavy analysis like phylogenetic analysis and high-throughput structural modeling for liability analysis. Using the IGX Platform, researchers improve their candidate selection by making accurate developability predictions for thousands of sequences at the same time, in a secure, intuitive environment.

"ENPICOM has transformed our toolset for antibody discovery," said Walters. "We are now even better equipped to discover the antibodies for our clients’ most challenging targets, enabling them to bring new therapeutic antibodies to the clinic and develop a new generation of drugs to treat life-threatening diseases."

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in